Trinity Biotech plc
TRIBNASDAQHealthcare● Active
$0.68
+$0.01(+1.87%)
Market Cap$7063227
P/E Ratio—
52W High$3.44
52W Low$0.5
Trinity Biotech plc (TRIB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TRIB · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
-$0.90
Est. -$0.32 · -181.3%
Revenue
$0.01B
Est. $0.01B · -26.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
TRIB reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 3, 2026 | -$0.26 | — | — | — | $0.01B | — |
| ◌ Q2 FY2026 | May 21, 2026 | -$0.31 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | Apr 30, 2026 | -$0.32 | -$0.90 | -181.3% | $0.01B | $0.01B | -26.2% |
| ▲ Q4 FY2025 | Dec 23, 2025 | -$0.51 | -$0.32 | +37.3% | $0.01B | $0.01B | +35.7% |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.30 | -$1.02 | -240.0% | $0.02B | $0.02B | -0.9% |
| ▲ Q1 FY2025 | Jan 29, 2025 | -$0.54 | -$0.06 | +88.9% | $0.02B | — | — |
| ▲ Q4 FY2024 | Nov 15, 2024 | -$0.54 | -$0.43 | +20.4% | $0.02B | $0.02B | -8.2% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -$0.67 | -$0.71 | -6.0% | $0.02B | $0.01B | +5.6% |
Q3 FY2026
Sep 3, 2026
EPS Actual
—
EPS Est.
-$0.26
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 21, 2026
EPS Actual
—
EPS Est.
-$0.31
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Miss
EPS Actual
-$0.90
EPS Est.
-$0.32
EPS Surpr.
-181.3%
Revenue
$0.01B
Q4 FY2025
Dec 23, 2025Beat
EPS Actual
-$0.32
EPS Est.
-$0.51
EPS Surpr.
+37.3%
Revenue
$0.01B
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$1.02
EPS Est.
-$0.30
EPS Surpr.
-240.0%
Revenue
$0.02B
Q1 FY2025
Jan 29, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.54
EPS Surpr.
+88.9%
Revenue
$0.02B
Q4 FY2024
Nov 15, 2024Beat
EPS Actual
-$0.43
EPS Est.
-$0.54
EPS Surpr.
+20.4%
Revenue
$0.02B
Q3 FY2024
Aug 14, 2024Miss
EPS Actual
-$0.71
EPS Est.
-$0.67
EPS Surpr.
-6.0%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q3 FY2026 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q2 FY2026 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q1 FY2026 | $-0.31 | $-0.31 | $-0.31 | 1 |
| Q4 FY2025 | $-0.32 | $-0.32 | $-0.32 | 1 |
| Q3 FY2025 | $-0.37 | $-0.37 | $-0.37 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 30, 2026 | -181.3% | $0.60 | $0.60 | +0.00% |
| ▲ Q4 FY2025 | Dec 23, 2025 | +37.3% | $0.89 | $1.28 | +43.50% |
| ▼ Q2 FY2025 | May 15, 2025 | -240.0% | $0.80 | $0.84 | +4.50% |
| ▲ Q1 FY2025 | Jan 29, 2025 | +88.9% | $1.36 | $1.32 | -2.94% |
| ▲ Q4 FY2024 | Nov 15, 2024 | +20.4% | $1.48 | $1.37 | -7.43% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -6.0% | $2.46 | $2.53 | +2.85% |
| ▲ Q2 FY2024 | May 23, 2024 | +37.7% | $1.56 | $1.63 | +4.49% |
| ▼ Q1 FY2024 | Jan 31, 2024 | -2.9% | $2.17 | $2.95 | +35.94% |
Q2 FY2026+0.00%
Report Date
Apr 30, 2026
EPS Beat/Miss
-181.3%
Price Before
$0.60
Price After
$0.60
Q4 FY2025+43.50%
Report Date
Dec 23, 2025
EPS Beat/Miss
+37.3%
Price Before
$0.89
Price After
$1.28
Q2 FY2025+4.50%
Report Date
May 15, 2025
EPS Beat/Miss
-240.0%
Price Before
$0.80
Price After
$0.84
Q1 FY2025-2.94%
Report Date
Jan 29, 2025
EPS Beat/Miss
+88.9%
Price Before
$1.36
Price After
$1.32
Q4 FY2024-7.43%
Report Date
Nov 15, 2024
EPS Beat/Miss
+20.4%
Price Before
$1.48
Price After
$1.37
Q3 FY2024+2.85%
Report Date
Aug 14, 2024
EPS Beat/Miss
-6.0%
Price Before
$2.46
Price After
$2.53
Q2 FY2024+4.49%
Report Date
May 23, 2024
EPS Beat/Miss
+37.7%
Price Before
$1.56
Price After
$1.63
Q1 FY2024+35.94%
Report Date
Jan 31, 2024
EPS Beat/Miss
-2.9%
Price Before
$2.17
Price After
$2.95
Avg Beat Reaction+9.41%
Avg Miss Reaction+10.82%
Beat Rate4 / 8 quarters
Largest Move+43.50% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TRIB ends December
Trinity Biotech plc (TRIB) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $-0.90 — missing the analyst consensus of $-0.32 by -181.3%. The next TRIB earnings date is expected around September 1, 2026.
Each quarter, investors track TRIB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TRIB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TRIB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TRIB earnings · 5 questionsTrinity Biotech plc's next earnings report is expected around September 1, 2026. TRIB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TRIB historically reports after market close (AMC).
TRIB earnings datewhen is TRIB earningsTRIB next earnings datewhen does TRIB report earningsTRIB earnings calendar
▸ Source: FMP · Trinity Biotech plc SEC filings · US GAAP · Trinity Biotech plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026